Search research articles
Contact Us
Filters
Showing results (191-200 of 343) with videos related to
Page
of 35
Sort By:
Oncotarget
|
May 12, 2016
RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer
Mingxin Zuo, Asif Rashid, Ying Wang, et al.
Investigational New Drugs
|
January 29, 2010
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
Bassel Fuad El-Rayes, Philip A Philip, Fazlul H Sarkar, et al.
Cancer
|
December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials
Fen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors
Alberto A Chiappori, S Gail Eckhardt, Ronald Bukowski, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Journal of Hematology & Oncology
|
May 30, 2015
HER2/neu-directed therapy for biliary tract cancer
Milind Javle, Chaitanya Churi, HyunSeon C Kang, et al.
Cancer Medicine
|
June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
Jane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
The Oncologist
|
May 11, 2017
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Talia Golan, Maria Raitses-Gurevich, Robin K Kelley, et al.
Human Pathology
|
February 11, 2014
Molecular characterization of gallbladder cancer using somatic mutation profiling
Milind Javle, Asif Rashid, Chaitanya Churi, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m<i>IDH1</i> cholangiocarcinoma
J W Valle, G K Abou-Alfa, R K Kelley, et al.
Page
of 35
Search research articles
Search
Showing results (191-200 of 343) with videos related to
Sort By:
Page
of 35
Oncotarget
|
May 12, 2016
RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer
Mingxin Zuo, Asif Rashid, Ying Wang, et al.
Investigational New Drugs
|
January 29, 2010
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
Bassel Fuad El-Rayes, Philip A Philip, Fazlul H Sarkar, et al.
Cancer
|
December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials
Fen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2007
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors
Alberto A Chiappori, S Gail Eckhardt, Ronald Bukowski, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Journal of Hematology & Oncology
|
May 30, 2015
HER2/neu-directed therapy for biliary tract cancer
Milind Javle, Chaitanya Churi, HyunSeon C Kang, et al.
Cancer Medicine
|
June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
Jane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
The Oncologist
|
May 11, 2017
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Talia Golan, Maria Raitses-Gurevich, Robin K Kelley, et al.
Human Pathology
|
February 11, 2014
Molecular characterization of gallbladder cancer using somatic mutation profiling
Milind Javle, Asif Rashid, Chaitanya Churi, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with m<i>IDH1</i> cholangiocarcinoma
J W Valle, G K Abou-Alfa, R K Kelley, et al.
Page
of 35